New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland New concepts and guidelines in the management of LDL-C and CV Risk: Need for early intervention 1.Need for improvement in managment of cardiovascular risk 2.What do current guidelines propose ? 3.What needs to be explored recommendations ? beyond current guideline Clinical presentation of coronary disease First clinical presentation of coronary artery disease is frequently an acute coronary syndrome. i.e. can be the last … Men 62 % Women 46 % 0 20 40 60 Patients (%) Framingham Heart Study Murabito et al Circulation 1993; 88: 2548-54 Courtasy of John Deanfield Frequency and mortality of a first coronary event 28.9 % 9.5 % 61.6 % 384,597 Individuals with first coronary event (Coronary death or first acute myocardial infarction – population aged 35-84) Dudas K et al.; Circulation 2011; 123: 46-52 Recommendations regarding risk estimation European Heart Journal 2012;33:1635–1701 Estimated risk as a function of high-density lipoprotein-cholesterol (HDL-C) for women in populations at high cardiovascular disease risk Eur Heart J 2011;32(14):1769-1818 Atherosclerosis 2011;217(1):3-46 SCORE charts with HDL-C SCORE charts with HDL-C For use in low risk regions: HDL-C= 0.8 mmol/L (32 mg/dl) For use in low risk regions: HDL-C= 1.8 mmol/L (70 mg/dl) Eur Heart J 2011;32(14):1769-1818 Atherosclerosis 2011;217(1):3-46 Intervention strategies as a function of total CV risk and LDL-C level Eur Heart J 2011;32(14):1769-1818 Atherosclerosis 2011;217(1):3-46 Recommendations for lipid analyses as treatment target in the prevention of CVD Eur Heart J 2011;32(14):1769-1818 Atherosclerosis 2011;217(1):3-46 European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) Eur Heart J 2012;33:1635-1701 Recommendations for genetic testing European Heart Journal 2012;33:1635–1701 Comparison of different imaging and circulating biomarkers for cardiovascular risk estimation •- Multi-Ethnic Study of Atherosclerosis (MESA) analysis -FRS >5%-<20%: 1330 intermediate risk subjects (from 6814 subjects), • 7.6 years of follow-up -6 markers: • coronary artery calcium, • carotid intima-media thickness, • ankle-brachial index, • brachial flow-mediated dilation, • high-sensitivity C-reactive protein (CRP), • family history of coronary heart disease (CHD) • Conclusions: Coronary artery calcium, ankle-brachial index, highsensitivity CRP, and family history were independent predictors of incident CHD/CVD in intermediate-risk individuals. • Coronary artery calcium provided superior discrimination and risk reclassification compared with other risk markers. Yeboah J et al.; JAMA. 2012 Aug 22;308(8):788-95 Recommendations on management of hyperlipidaemia European Heart Journal 2012;33:1635–1701 Is there evidence for a benefit of statin therapy in people at low risk of vascular disease ? Interpretation: In individuals with 5-year risk of major vascular events lower than 10%, each 1 mmol/L reduction in LDL cholesterol produced an absolute reduction in major vascular events of about 11 per 1000 over 5 years. This benefit greatly exceeds any known hazards of statin therapy. Under present guidelines, such individuals would not typically be regarded as suitable for LDL-lowering statin therapy. The present report suggests, therefore, that these guidelines might need to be reconsidered. Cholesterol Treatment Trialists' (CTT) Collaborators; Lancet. 2012 Aug 11; 380(9841):581-90 Is there evidence for a benefit of statin therapy in people at low risk of vascular disease ? Cholesterol Treatment Trialists' (CTT) Collaborators; Lancet. 2012 Aug 11; 380(9841):581-90 Major vascular events avoided in different cardiovascular risk cohorts categories Cholesterol Treatment Trialists' (CTT) Collaborators; Lancet. 2012 Aug 11; 380(9841):581-90 Recommendations for treatment targets for LDL-C Eur Heart J 2011;32(14):1769-1818 Atherosclerosis 2011;217(1):3-46 JAMA. 2012 Mar 28;307(12):13 Comparison HPS2-THRIVE and Aim-High trial AIM-HIGH trial HPS2-THRIVE trial (N Engl J Med 2011) • Pre-randomisation phase with niacin (1.5/2g) exclusion: 20.1 % • Pre-randomisation phase with ER-niacin (2g)/ laropiprant exclusion: 25.4 % • Aiming to have similarly low LDL-C in both treatment groups LDL: - 5.5 %, HDL: + 13.2 % • No further adjustment of LDL-C levels after randomization LDL: -20 %; HDL + 17 % More patients on high-dose statin or ezetimibe in control-group Addition of laropiprant (Antagonist of PGD2 receptor DP1) • Randomization (n): 1718 vs. 1696 patients • Randomization (n): 12838 vs. 12835 patients • Mean FU - 3 years (556 events) • Mean FU - 4 years (? events) HPS2-THRIVE clinical outcome data (presentation expected in 2013) Lipid-targeted Therapies What should be added to statins in patients with high vascular risk ? Statin therapy Further LDL-C • NPC1L1 (Ezetimibe*) HDL-C Combined LDL-C HDL-C • PCSK9 inhibition (Monoclonal Ab*) • Niacin/Laropiprant* • ApoB-100 Antisense oligonucleotides • CETP inhibition (Anacetrapib*, Evacetrapib*) *Clinical outcome trials ongoing • Reconstituted HDLs • ApoA1 modulation HDL metabolism – HDL-C can be increased by several mechanisms (2) apoA-I (lipid-free) (3) ABCA-1 expression (4) SR-BI inhibition (1) CETP inhibition Besler C et al. & Landmesser U. EMBO Mol Med 2012; 4(4):251-68